Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?
Gespeichert in:
| Titel: | Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized? |
|---|---|
| Autoren: | Scheen, André |
| Quelle: | Expert Review of Clinical Pharmacology. 16:1053-1062 |
| Verlagsinformationen: | Informa UK Limited, 2023. |
| Publikationsjahr: | 2023 |
| Schlagwörter: | Cardiotonic Agents, GLP-1 receptor agonist, heart failure, Cardiotonic Agents/pharmacology, gliflozin, Systèmes cardiovasculaire & respiratoire, Sciences de la santé humaine, Glucagon-Like Peptide-1 Receptor, Hypoglycemic Agents/adverse effects, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, metabolism & nutrition, Cardiovascular & respiratory systems, Glucagon-Like Peptide-1 Receptor/agonists, Humans, Hypoglycemic Agents, Atherosclerosis/complications, Human health sciences, Pharmacy, pharmacology & toxicology, Heart Failure, Cardiovascular Diseases/prevention & control/complications, SGLT2 inhibitor, Pharmacie, pharmacologie & toxicologie, Heart Failure/drug therapy, real-world clinical practice, Atherosclerosis, 3. Good health, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Cardiovascular Diseases, Atherosclerotic cardiovascular disease, cardiovascular outcome trial, Diabetes Mellitus, Type 2/complications/drug therapy, Endocrinologie, métabolisme & nutrition |
| Beschreibung: | Atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) are two major complications of type 2 diabetes (T2DM). Cardiovascular protection is a key objective, yet not fully reached in clinical practice.Both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) have proven their efficacy in reducing major cardiovascular events in high-risk patients with T2DM and SGLT2is in reducing hospitalization for HF in placebo-controlled randomized trials. However, real-life studies worldwide revealed that only a minority of patients with T2DM receive either a GLP-1RA or an SGLT2i and surprisingly even less patients with established ASCVD or HF are treated with these cardioprotective antihyperglycemic agents.Bridging the gap between evidence-based cardiovascular protection with GLP-1RAs and SGLT2is and their underuse in daily clinical practice in patients with T2DM at high risk is crucial from a public health viewpoint. However, the task appears hazardous and the goal not attained considering the current failure. Education of specialists/primary care physicians and patients is critical. Multifaceted and coordinated interventions involving all actors (physicians, patients and broadly health-care system) must be implemented to stimulate the adoption of these cardioprotective antihyperglycemic medications as part of routine cardiovascular care among patients with T2DM. |
| Publikationsart: | Article |
| Sprache: | English |
| ISSN: | 1751-2441 1751-2433 |
| DOI: | 10.1080/17512433.2023.2279193 |
| Zugangs-URL: | https://pubmed.ncbi.nlm.nih.gov/37919944 https://hdl.handle.net/2268/312538 https://doi.org/10.1080/17512433.2023.2279193 |
| Dokumentencode: | edsair.doi.dedup.....28da24ceaf8e7e5c872c49f1d6c85a59 |
| Datenbank: | OpenAIRE |
Nájsť tento článok vo Web of Science | Abstract: | Atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) are two major complications of type 2 diabetes (T2DM). Cardiovascular protection is a key objective, yet not fully reached in clinical practice.Both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) have proven their efficacy in reducing major cardiovascular events in high-risk patients with T2DM and SGLT2is in reducing hospitalization for HF in placebo-controlled randomized trials. However, real-life studies worldwide revealed that only a minority of patients with T2DM receive either a GLP-1RA or an SGLT2i and surprisingly even less patients with established ASCVD or HF are treated with these cardioprotective antihyperglycemic agents.Bridging the gap between evidence-based cardiovascular protection with GLP-1RAs and SGLT2is and their underuse in daily clinical practice in patients with T2DM at high risk is crucial from a public health viewpoint. However, the task appears hazardous and the goal not attained considering the current failure. Education of specialists/primary care physicians and patients is critical. Multifaceted and coordinated interventions involving all actors (physicians, patients and broadly health-care system) must be implemented to stimulate the adoption of these cardioprotective antihyperglycemic medications as part of routine cardiovascular care among patients with T2DM. |
|---|---|
| ISSN: | 17512441 17512433 |
| DOI: | 10.1080/17512433.2023.2279193 |